Starczynowski Lab

Publications

Laranjeira, AB A; Kong, T; Snyder, SC; Fulbright, MC; Fisher, DA C; Starczynowski, DT; Oh, ST. In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood. 2024; 143:2414-2424.

Matsui, S; Ri, C; Bolanos, LC; Choi, K; Shibamiya, A; Ishii, A; Takaishi, K; Oshima-Hasegawa, N; Tsukamoto, S; Takeda, Y; Yokote, K; Starczynowski, DT; Sakaida, E; Muto, T. Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia. 2024; 38:1032-1045.

Riabov, V; Xu, Q; Schmitt, N; Streuer, A; Ge, G; Bolanos, L; Wunderlich, M; Jann, JC; Wein, A; Altrock, E; Steiner, L; Jawhar, M; Hofmann, WK; Nowak, D. ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms. Haematologica: the hematology journal. 2024; 109:1426-1438.

Aggarwal, RK; Sidoli, S; Sahu, S; Aluri, S; Vegivinti, C; Verma, D; Gordon-Mitchell, S; Agarwal, B; Verma, T; Starczynowski, DT; LaFave, LM; Cheng, H; Verma, A; Zou, Y. Abstract 1464: Smoking carcinogen-induced inflammation promotes lung carcinogenesis via IRAK4 activation. Cancer Research. 2024; 84:1464.

Babic, I; Bryan, N; Cunningham, C; Sampson, A; Starczynowski, D; Nurmemmedov, E. Abstract 3092: MICRO-TAG: A novel fluorescence-based real-time cellular target engagement platform for drug discovery. Cancer Research. 2024; 84:3092.

Garcia-Manero, G; Platzbecker, U; Lim, K; Nowakowski, G; Abdel-Wahab, O; Kantarjian, H; Verma, A; Starczynowski, DT. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer. 2024; 3:1339870.

Ishikawa, C; Barreyro, L; Sampson, A; Hueneman, K; Choi, K; Bolanos, LC; Volk, A; Watowich, SS; Greis, K; Starczynowski, DT. UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies. Blood. 2023; 142:2762.

Walulik, S; Dean, S; Vick, EJ; Zhu, X; Wunderlich, M; Chou, C; Choi, K; Grimes, HL; Starczynowski, DT; Miles, LA; Volk, A. The Mechanism of Therapy Resistance By Lineage Plasticity in AML and How to Overcome It. Blood. 2023; 142:1410.

Elgamal, OA; Zapata, JC; Li, H; Sharpe, C; Fobare, S; Stearns, B; Lerma, JR; Bryant, K; Furby, C; Long, M; Burd, A; Pauza, CD; Hertlein, EK; Byrd, JC. Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML. Blood. 2023; 142:1544.

Uible, EE; Choi, K; Hueneman, K; Bolanos, LC; Greis, K; Starczynowski, DT. The Zymogen Form of Caspase-1 Is Required to Fine Tune Excessive Cell-Intrinsic Inflammation in Acute Myeloid Leukemia. Blood. 2023; 142:1391.

Rosenbaum, JS; Kolt, AS; Hoyt, SB; Hayes, GM; Soldo, BL; Thomas, CJ; Starczynowski, DT. Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients. Blood. 2023; 142:4152.

LeBlanc, F; Bennett, J; Choi, K; Starczynowski, DT. Targeting CREB-Binding Protein (CREBBP) Overcomes Resistance to Azacitidine and Venetoclax Therapy in Acute Myeloid Leukemia (AML). Blood. 2023; 142:5765.

Cochran, AE; Hassan, A; Hueneman, K; Choi, K; Starczynowski, DT. Defective Necroptosis Mediates Chemotherapy Resistance in AML. Blood. 2023; 142:1394.

Laranjeira, AB A; Kong, T; Snyder, SC; Fulbright, MC; Fisher, DA C; Starczynowski, DT; Oh, ST. In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms. Blood. 2023; 142:991.

Vick, EJ; Bennett, J; Cochran, AE; Hueneman, K; Bolanos, LC; Zhang, X; McKnight, C; Ceribelli, M; Klumpp-Thomas, C; Choi, K; Greis, K; Thomas, CJ; Starczynowski, DT. Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies. Blood. 2023; 142:45.

Matsui, S; Ri, C; Bolanos, LC; Choi, K; Shibamiya, A; Ishii, A; Takaishi, K; Oshima-Hasegawa, N; Tsukamoto, S; Takeda, Y; Mimura, N; Yokote, K; Starczynowski, DT; Sakaida, E; Muto, T. Regulation of Metabolic Homeostasis By TRAF6 Contributes to the Leukemia Progression. Blood. 2023; 142:1370.

Stahl, M; Bewersdorf, JP; Xie, Z; Porta, MG D; Komrokji, R; Xu, ML; Abdel-Wahab, O; Taylor, J; Steensma, DP; Starczynowski, DT; Wei, AH; Santini, V; Savona, MR; Zeidan, AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews. 2023; 62:101128.

Xie, Z; Starczynowski, DT. Are DDX41 variants of unknown significance and pathogenic variants created equal?. Haematologica: the hematology journal. 2023; 108:2883-2885.

Gorak, EJ; Otterstatter, M; Al Baghdadi, T; Gillis, N; Foran, JM; Liu, JJ; Bejar, R; Gore, SD; Kroft, SH; Harrington, A; Walker, ME; Padron, E; DeZern, AE; Sekeres, MA. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood Advances. 2023; 7:6120-6129.

Muto, T; Walker, CS; Agarwal, P; Vick, E; Sampson, A; Choi, K; Niederkorn, M; Ishikawa, C; Hueneman, K; Varney, M; Starczynowski, DT. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica: the hematology journal. 2023; 108:2715-2729.

Bennett, J; Ishikawa, C; Agarwal, P; Yeung, J; Sampson, A; Uible, E; Vick, E; Bolanos, LC; Hueneman, K; Wunderlich, M; Rosenbaum, J; Hoyt, SB; Thomas, CJ; Starczynowski, DT. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. Blood. 2023; 142:989-1007.

Dean, ST; Ishikawa, C; Zhu, X; Walulik, S; Nixon, T; Jordan, JK; Henderson, S; Wyder, M; Salomonis, N; Wunderlich, M; Greis, KD; Starczynowski, DT; Volk, AG. Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development. Blood Advances. 2023; 7:4822-4837.

Marion, W; Koppe, T; Chen, CC; Wang, D; Frenis, K; Fierstein, S; Sensharma, P; Aumais, O; Peters, M; Ruiz-Torres, S; Ebert, BL; Starczynowski, D; da Rocha, EL; Rowe, RG. RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia. Leukemia. 2023; 37:1698-1708.

Bewersdorf, JP; Xie, Z; Bejar, R; Borate, U; Boultwood, J; Brunner, AM; Buckstein, R; Carraway, HE; Churpek, JE; Daver, NG; Xu, ML; Savona, MR; Wei, AH; Zeidan, AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews. 2023; 60:101072.

Stahl, M; Abdel-Wahab, O; Wei, AH; Savona, MR; Xu, ML; Xie, Z; Taylor, J; Starczynowski, D; Sanz, GF; Sallman, DA; Steensma, DP; Sekeres, MA; Buckstein, RJ; Zeidan, AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances. 2023; 7:2709-2714.

Chlon, TM; Stepanchick, E; Sulentic, A; Wilson, A; Starczynowski, DT. Abstract A46: Heterozygous mutations in DDX41 cause erythroid progenitor cell defects and cooperate with p53 mutations to cause hematologic malignancy. 2023; 4:a46.

Babic, I; Bryan, N; Cunningham, C; Sampson, A; Starczynowski, D; Nurmemmedov, E. Abstract 2759: Real-time cellular target engagement and protein quantification for drug discovery. Cancer Research. 2023; 83:2759.

Starczynowski, DT. 1031 – FROM PRE-LEUKEMIC STATES TO MALIGNANT TRANSFORMATION: UNRAVELING THE ROLE OF DYSREGULATED INNATE IMMUNE SIGNALING AND INFLAMMATION IN MYELOID MALIGNANCIES. Experimental Hematology. 2023; 124:s35.

Zhang, Y; Chen, X; Wang, H; Gordon-Mitchell, S; Sahu, S; Bhagat, TD; Choudhary, G; Aluri, S; Pradhan, K; Sahu, P; Starczynowski, D; Steidl, U; Maitra, A; Verma, A. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. Journal of Hematology and Oncology. 2022; 15:70.

Zeidan, AM; Bewersdorf, JP; Buckstein, R; Sekeres, MA; Steensma, DP; Platzbecker, U; Loghavi, S; Boultwood, J; Bejar, R; Bennett, JM; Savona, MR; Wei, AH; Abdel-Wahab, O; Santini, V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022; 36:2939-2946.

Dean, S; Ishikawa, C; Zhu, X; Nixon, T; Walulik, S; Wyder, M; Jordan, J; Wunderlich, M; Starczynowski, DT; Salomonis, N; Greis, K; Volk, A. TRIM13 Is a Novel Cell Cycle Hub Regulated By CHAF1B to Promote Acute Myeloid Leukemogenesis. Blood. 2022; 140:2978-2979.

Bennett, J; Yeung, J; Sampson, A; Hueneman, K; Wunderlich, M; Choi, K; Volk, A; Hoyt, SB; Thomas, CJ; Starczynowski, DT. IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML. Blood. 2022; 140:2240-2241.

Ishikawa, C; Barreyro, L; Sampson, A; Hueneman, K; Choi, K; Bolanos, LC; Volk, A; Greis, KD; Starczynowski, DT. UBE2N Is a Druggable Target and an Essential Ubiquitin-Conjugating Enzyme in Myeloid Malignancies. Blood. 2022; 140:5830.

Riabov, V; Xu, Q; Schmitt, N; Streuer, A; Ge, G; Jann, J; Wein, A; Altrock, E; Rapp, F; Nowak, V; Steiner, L; Hofmann, W; Nowak, D; Jawhar, M. ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes. Blood. 2022; 140:9749-9750.

Rosenbaum, JS; Hoyt, SB; Kolt, AS; Luedtke, DA; Thomas, CJ; Starczynowski, DT. Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML. Blood. 2022; 140:5949-5950.

Agarwal, P; Sampson, A; Hueneman, K; Choi, K; Zhao, X; Galloway-Pena, J; Setchell, K; Starczynowski, DT. A Circulating Microbial Metabolite Drives the Clonal Expansion of Pre-Leukemic Cells. Blood. 2022; 140:975-976.

Yeaton, A; Cayanan, G; Loghavi, S; Dolgalev, I; Leddin, EM; Loo, CE; Torabifard, H; Nicolet, D; Wang, J; Corrigan, K; Tsirigos, A; Eisfeld, AK; Aifantis, I; Guillamot, M. The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer Discovery. 2022; 12:2392-2413.

Choudhary, GS; Pellagatti, A; Agianian, B; Smith, MA; Bhagat, TD; Gordon-Mitchell, S; Sahu, S; Pandey, S; Shah, N; Aluri, S; Gavathiotis, E; Boultwood, J; Starczynowski, DT; Verma, A. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. eLife. 2022; 11:e78136.

Jones, LQ M; Starczynowski, DT. IKAROS and MENIN in synergy in AML. Nature Cancer. 2022; 3:528-529.

Barreyro, L; Sampson, AM; Ishikawa, C; Hueneman, KM; Choi, K; Pujato, MA; Chutipongtanate, S; Wyder, M; Haffey, WD; O'Brien, E; Greis, KD; Nurmemmedov, E; Seibel, WL; Starczynowski, DT. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 2022; 14:eabb7695.

Azhar, M; Kincaid, Z; Kesarwani, M; Ahmed, A; Wunderlich, M; Latif, T; Starczynowski, D; Azam, M. Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Advances. 2022; 6:1186-1192.

Muto, T; Guillamot, M; Yeung, J; Fang, J; Bennett, J; Nadorp, B; Lasry, A; Redondo, LZ; Choi, K; Gong, Y; Lujambio, A; Lowe, SW; Aifantis, I; Starczynowski, DT. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022; 29:298-314.e9.

Niederkorn, M; Ishikawa, C; M. Hueneman, K; Bartram, J; Stepanchick, E; R. Bennett, J; E. Culver-Cochran, A; Bolanos, LC; Uible, E; Choi, K; Wunderlich, M; Perentesis, JP; M. Chlon, T; Filippi, MD; Starczynowski, DT. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. 2022; 36:438-451.

Bennett, J; Starczynowski, DT. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology. 2022; 29:8-19.

Aoyagi, Y; Hayashi, Y; Harada, Y; Choi, K; Matsunuma, N; Sadato, D; Maemoto, Y; Ito, A; Yanagi, S; Starczynowski, DT; Harada, H. Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. Cancer Discovery. 2022; 12:250-269.

Chlon, TM; Stepanchick, E; Hershberger, CE; Daniels, NJ; Hueneman, KM; Kuenzi Davis, A; Choi, K; Zheng, Y; Gurnari, C; Haferlach, T; Padgett, RA; Maciejewski, JP; Starczynowski, DT. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021; 28:1966-1981.e6.

Agarwal, P; Li, H; Choi, K; Hueneman, K; He, J; Welner, RS; Starczynowski, DT; Bhatia, R. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling. Cell Reports. 2021; 36:109386.

Trowbridge, JJ; Starczynowski, DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. The Journal of Experimental Medicine. 2021; 218:e20201544.

Wang, T; Pine, AR; Kotini, AG; Yuan, H; Zamparo, L; Starczynowski, DT; Leslie, C; Papapetrou, EP. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell. 2021; 28:1074-1089.e7.

Serrano-Lopez, J; Hegde, S; Kumar, S; Serrano, J; Fang, J; Wellendorf, AM; Roche, PA; Rangel, Y; Carrington, LJ; Geiger, H; Maillard, I; Sanchez-Garcia, J; Starczynowski, DT; Cancelas, JA. Systemic inflammation recruits fast-acting anti-inflammatory innate myeloid progenitors from BM into lymphatics. eLife. 2021; 10:1-60.

Serrano-Lopez, J; Hegde, S; Kumar, S; Serrano, J; Fang, J; Wellendorf, AM; Roche, PA; Rangel, Y; Carrington, LJ; Geiger, H; Maillard, I; Sanchez-Garcia, J; Starczynowski, DT; Cancelas, JA. Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics. eLife. 2021; 10:e66190.

Jones, L; Melgar, K; Hoyt, S; Wunderlich, M; O’Brien, E; Perentesis, J; Thomas, C; Starczynowski, D. 81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML. Journal of Clinical and Translational Science. 2021; 5:100.

Smith, MA; Culver-Cochran, AE; Adelman, ER; Rhyasen, GW; Ma, A; Figueroa, ME; Starczynowski, DT. TNFAIP3 Plays a Role in Aging of the Hematopoietic System. Frontiers in Immunology. 2020; 11:536442.

Schieber, M; Marinaccio, C; Bolanos, LC; Haffey, WD; Greis, KD; Starczynowski, DT; Crispino, JD. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Blood Cancer Journal. 2020; 10:98.

Starczynowski, DT. HHEX expression drives AML development. Blood. 2020; 136:1575-1576.

Niederkorn, M; Agarwal, P; Starczynowski, DT. TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. Experimental Hematology. 2020; 90:18-29.

Muto, T; Walker, CS; Choi, K; Hueneman, K; Smith, MA; Gul, Z; Garcia-Manero, G; Ma, A; Zheng, Y; Starczynowski, DT. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology. 2020; 21:535-545.

Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J; Wilson, KM; Zhang, X; Shen, J; Jiang, F; O'Brien, E; Perentesis, JP; Starczynowski, DT; Thomas, CJ. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. The Journal of Clinical Investigation. 2020; 130:2017-2023.

Niederkorn, M; Hueneman, K; Choi, K; Varney, ME; Romano, L; Pujato, MA; Greis, KD; Inoue, J; Meetei, R; Starczynowski, DT. TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. Cell Reports. 2020; 30:2776-2790.e6.